National Aeronautics and Space Administration July 24, 2007 – Federal Register Recent Federal Regulation Documents

Insurance Requirement for Maximum Probable Loss (MPL) With Respect to Launch of Alliant Techsystems Inc. (ATK) ALV-X1 Suborbital Launch Vehicle at Wallops Flight Facility
Document Number: E7-14294
Type: Notice
Date: 2007-07-24
Agency: National Aeronautics and Space Administration, Agencies and Commissions
This notice is issued in accordance with 42 U.S.C. 2458c(b)(2)(B). Per statute, NASA is required to publish the amount of insurance required when a party to an agreement between the Administration and the party, made for the purpose of developing new technology for an experimental aerospace vehicle, has requested indemnification. For the demonstration launch of ATK's new suborbital ALV-X1 launch vehicle at NASA's Wallops Flight Facility, carrying experimental aerospace vehicle payloads, as defined in 42 U.S.C. 2458c(d)(3), scheduled for the 1st quarter of Fiscal Year 2008, the Administrator has determined the maximum probable loss to be $15.4 million for Government property, $180,000 for 3rd party property, and $9 million for 3rd party personnel. As a condition for indemnification, analogous to that required by the Commercial Space Launch Act, ATK is required to carry insurance to cover the MPL. Per statute, conditional indemnification may only be provided upon ATK's successful passage of a NASA safety review, and certification of adequate insurance coverage.
Notice of Intent To Grant Exclusive License
Document Number: E7-14291
Type: Notice
Date: 2007-07-24
Agency: National Aeronautics and Space Administration, Agencies and Commissions
This notice is issued in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant an exclusive license worldwide to practice the invention described and claimed in U.S. Patent No. 7,179,217, entitled ``Apparatus for Enhancing Tissue Repair in Mammals'', to Regenetech, Inc., having its principal place of business in Houston, Texas. The patent is jointly owned by NASA and Regenetech. The NASA-owned patent rights in this invention have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.